Related Experiment Video
Updated: Aug 8, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Roflumilast for asthma and chronic obstructive pulmonary disease
Issues in Emerging Health Technologies
|December 2, 2005
Summary
Roflumilast, a PDE4 inhibitor, improved lung function and reduced exacerbations in asthma and COPD patients. Further research is needed to confirm its clinical outcomes and role in treatment.
Area of Science:
- Pharmacology
- Pulmonology
- Inflammation
Background:
- Roflumilast targets phosphodiesterase-IV (PDE4), an enzyme implicated in airway inflammation.
- Asthma and Chronic Obstructive Pulmonary Disease (COPD) are characterized by significant airway inflammation.
Purpose of the Study:
- To evaluate the efficacy of roflumilast in patients with asthma and COPD.
- To assess roflumilast's impact on lung function, rescue medication use, and exacerbations.
Main Methods:
- Clinical trials were conducted comparing roflumilast to inhaled beclomethasone in asthma and placebo in COPD.
- Key efficacy measures included forced expiratory volume in one second (FEV1) and peak expiratory flow (PEF).
Main Results:
- Roflumilast demonstrated significant improvements in FEV1 and PEF in both asthma and COPD populations.
- Reduced rescue medication use and fewer exacerbations were observed in COPD patients treated with roflumilast.
Conclusions:
- Roflumilast shows potential in improving lung function and reducing exacerbations in asthma and COPD.
- Current evidence is primarily from non-peer-reviewed abstracts, necessitating further studies for clinical outcome validation.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...